Cerbios-Pharma SA (from now on Cerbios) and XSpray Microparticles AB (from now on XSpray) have signed a letter of intent to develop a longterm, mutually beneficial collaboration whereby XSpray will be the preferred technology provider and Cerbios will be the preferred manufacturer for the joint development of HPAI (High Potency Active Ingredients) products with unique characteristics